Microsomal transfer protein (MTP) inhibition - A novel approach to the treatment of homozygous hypercholesterolemia

Annals of Medicine

Volumn 46, Issue 7, 2014, Pages 464-474

  Sirtori, Cesare R ^a,b   Pavanello, Chiara ^a,b   Bertolini, Stefano ^c  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Homozygous familial hypercholesterolemia; LDL apheresis; LDL C reduction; Lomitapide; MTP

Indexed keywords

APOLIPOPROTEIN B; ATORVASTATIN; ETHINYLESTRADIOL; EZETIMIBE; FENOFIBRATE; IMPLITAPIDE; KETOCONAZOLE; LOMITAPIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; MIPOMERSEN; NORGESTIMATE; SIMVASTATIN; VERY LOW DENSITY LIPOPROTEIN; WARFARIN; BENZIMIDAZOLE DERIVATIVE; CARRIER PROTEIN; HYPOCHOLESTEROLEMIC AGENT; LDLR PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN RECEPTOR;

AREA UNDER THE CURVE; ARTERY DISEASE; BIOLOGICAL FUNCTIONS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG METABOLISM; FAMILIAL HYPERCHOLESTEROLEMIA; FIRST PASS EFFECT; FOOD DRUG INTERACTION; HETEROZYGOSITY; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; LIPID DIET; LIPOPROTEIN SECRETION; MAXIMUM PLASMA CONCENTRATION; MICROSOME; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN INHIBITION; REGULATORY MECHANISM; REVIEW; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG INTERACTION; GENETICS; HOMOZYGOTE; HYPERCHOLESTEROLEMIA; METABOLISM; MUTATION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BENZIMIDAZOLES; CARRIER PROTEINS; DRUG INTERACTIONS; HOMOZYGOTE; HUMANS; HYPERCHOLESTEROLEMIA; MUTATION; RECEPTORS, LDL;

EID: 84910008640     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2014.931100     Document Type: Review

References (62)

1. Raal FJ, Santos RD. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis. 2012;223:262-8.
2. Marais AD, Blom DJ. Recent advances in the treatment of homozygous familial hypercholesterolaemia. Curr Opin Lipidol. 2013;24:288-94.
3. Rubinsztein DC, Raal FJ, Seftel HC, Pilcher G, Coetzee GA, van der Westhuyzen DR. Characterization of six patients who are double heterozygotes for familial hypercholesterolemia and familial defective apo B-100. Arterioscler Thromb. 1993;13:1076-81.
4. Pisciotta L, Priore Oliva C, Cefalu AB, Noto D, Bellocchio A, Fresa R, et al . Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia. Atherosclerosis. 2006;186:433-40.
5. Sjouke B, Kusters DM, Kindt I, Besseling J, Defesche JC, Sijbrands EJ, et al. Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. Eur Heart J. 2014 Feb 28. [Epub ahead of print]
6. Mabuchi H, Nohara A, Noguchi T, Kobayashi J, Kawashiri MA, Tada H, et al. Molecular genetic epidemiology of homozygous familial hypercholesterolemia in the Hokuriku district of Japan . Atherosclerosis. 2011;214:404-7.
7. Fahed AC, Safa RM, Haddad FF, Bitar FF, Andary RR, Arabi MT, et al. Homozygous familial hypercholesterolemia in Lebanon: a genotype/phenotype correlation. Mol Genet Metab. 2011;102:181-8.
8. Moorjani S, Roy M, Gagne C, Davignon J, Brun D, Toussaint M, et al. Homozygous familial hypercholesterolemia among French Canadians in Quebec Province. Arteriosclerosis. 1989;9:211-16.
9. Jelassi A, Slimani A, Jguirim I, Najah M, Maatouk F, Varret M, et al. Effect of a splice site mutation in LDLR gene and two variations in PCSK9 gene in Tunisian families with familial hypercholesterolaemia. Ann Clin Biochem. 2011;48(Pt 1):83-6.
10. Benn M, Watts GF, Tybjaerg-Hansen A, Nordestgaard BG. Familial hypercholesterolemia in the Danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab. 2012;97:3956-64.
11. Thompson GR, Catapano A, Saheb S, Atassi-Dumont M, Barbir M, Eriksson M, et al. Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe. Curr Opin Lipidol. 2010;21:492-8.
12. Cohen JC, Kimmel M, Polanski A, Hobbs HH. Molecular mechanisms of autosomal recessive hypercholesterolemia. Curr Opin Lipidol. 2003;14:121-7.
13. Arca M, Zuliani G, Wilund K, Campagna F, Fellin R, Bertolini S, et al. Autosomal recessive hypercholesterolaemia in Sardinia, Italy, and mutations in ARH: a clinical and molecular genetic analysis. Lancet. 2002;359:841-7.
14. Pisciotta L, Priore Oliva C, Pes GM, Di Scala L, Bellocchio A, Fresa R, et al. Autosomal recessive hypercholesterolemia (ARH) and homozygous familial hypercholesterolemia (FH): a phenotypic comparison. Atherosclerosis. 2006;188:398-405.
15. Innerarity TL, Mahley RW, Weisgraber KH, Bersot TP, Krauss RM, Vega GL, et al. Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia. J Lipid Res. 1990;31:1337-49.
16. Abifadel M, Guerin M, Benjannet S, Rabes JP, Le Goff W, Julia Z, et al. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia. Atherosclerosis. 2012;223:394-400.
17. Sirtori CR, Catapano AL, Franceschini G, Corsini A, Noseda G, Fragiacomo C, et al. Aortic and coronary atheromatosis in a woman with severe hypercholesterolaemia without LDL receptor alterations. Eur Heart J. 1991;12:818-24.
18. Naoumova RP, Neuwirth C, Lee P, Miller JP, Taylor KG, Soutar AK. Autosomal recessive hypercholesterolaemia: long-term follow up and response to treatment. Atherosclerosis. 2004;174:165-72.
19. Soufi M, Rust S, Walter M, Schaefer JR. A combined LDL receptor/LDL receptor adaptor protein 1 mutation as the cause for severe familial hypercholesterolemia. Gene. 2013;521:200-3.
20. Hobbs HH, Russell DW, Brown MS, Goldstein JL. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet. 1990;24:133-70.
21. Miltiadous G, Xenophontos S, Bairaktari E, Ganotakis M, Cariolou M, Elisaf M. Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia. Pharmacogenet Genomics. 2005;15:219-25.
22. Raper A, Kolansky DM, Cuchel M. Treatment of familial hypercholesterolemia: is there a need beyond statin therapy? Curr Atheroscler Rep. 2012;14:11-16.
23. Marais AD, Firth JC, Blom DJ. Homozygous familial hypercholesterolemia and its management. Semin Vasc Med. 2004;4:43-50.
24. Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ. Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation. 2013;128:2113-20.
25. Wetterau JR, Lin MC, Jamil H. Microsomal triglyceride transfer protein. Biochim Biophys Acta. 1997;1345:136-50.
26. Wetterau JR, Aggerbeck LP, Bouma ME, Eisenberg C, Munck A, Hermier M, et al. Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science. 1992;258:999-1001.
27. Sharp D, Blinderman L, Combs KA, Kienzle B, Ricci B, Wager-Smith K, et al. Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature. 1993;365:65-9.
28. Hussain MM, Rava P, Walsh M, Rana M, Iqbal J. Multiple functions of microsomal triglyceride transfer protein. Nutr Metab (Lond). 2012;9:14.
29. Wang S, McLeod RS, Gordon DA, Yao Z. The microsomal triglyceride transfer protein facilitates assembly and secretion of apolipoprotein B-containing lipoproteins and decreases cotranslational degradation of apolipoprotein B in transfected COS-7 cells. J Biol Chem. 1996;271:14124-33.
30. Atzel A, Wetterau JR. Identification of two classes of lipid molecule binding sites on the microsomal triglyceride transfer protein. Biochemistry. 1994;33:15382-8.
31. Khatun I, Walsh MT, Hussain MM. Loss of both phospholipid and triglyceride transfer activities of microsomal triglyceride transfer protein in abetalipoproteinemia. J Lipid Res. 2013;54:1541-9.
32. Larsson SL, Skogsberg J, Bjorkegren J. The low density lipoprotein receptor prevents secretion of dense apoB100-containing lipoproteins from the liver. J Biol Chem. 2004;279:831-6.
33. Shimano H, Shimomura I, Hammer RE, Herz J, Goldstein JL, Brown MS, et al. Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 gene. J Clin Invest. 1997;100:2115-24.
34. Sato R, Miyamoto W, Inoue J, Terada T, Imanaka T, Maeda M. Sterol regulatory element-binding protein negatively regulates microsomal triglyceride transfer protein gene transcription. J Biol Chem. 1999;274:24714-20.
35. Horton JD, Shimomura I, Brown MS, Hammer RE, Goldstein JL, Shimano H. Activation of cholesterol synthesis in preference to fatty acid synthesis in liver and adipose tissue of transgenic mice overproducing sterol regulatory element-binding protein-2. J Clin Invest. 1998;101:2331-9.
36. Tremblay AJ, Lamarche B, Ruel IL, Hogue JC, Bergeron J, Gagne C, et al. Increased production of VLDL apoB-100 in subjects with familial hypercholesterolemia carrying the same null LDL receptor gene mutation. J Lipid Res. 2004;45:866-72.
37. Millar JS, Maugeais C, Ikewaki K, Kolansky DM, Barrett PH, Budreck EC, et al. Complete deficiency of the low-density lipoprotein receptor is associated with increased apolipoprotein B-100 production. Arterioscler Thromb Vasc Biol. 2005;25:560-5.
38. Lin MC, Arbeeny C, Bergquist K, Kienzle B, Gordon DA, Wetterau JR. Cloning and regulation of hamster microsomal triglyceride transfer protein. The regulation is independent from that of other hepatic and intestinal proteins which participate in the transport of fatty acids and triglycerides. J Biol Chem. 1994;269:29138-45.
39. Bennett AJ, Billett MA, Salter AM, White DA. Regulation of hamster hepatic microsomal triglyceride transfer protein mRNA levels by dietary fats. Biochem Biophys Res Commun. 1995;212:473-8.
40. Dorfman SE, Wang S, Vega-Lopez S, Jauhiainen M, Lichtenstein AH. Dietary fatty acids and cholesterol differentially modulate HDL cholesterol metabolism in Golden-Syrian hamsters. J Nutr. 2005;135:492-8.
41. Hagan DL, Kienzle B, Jamil H, Hariharan N. Transcriptional regulation of human and hamster microsomal triglyceride transfer protein genes. Cell type-specific expression and response to metabolic regulators. J Biol Chem. 1994;269:28737-44.
42. Lin MC, Gordon D, Wetterau JR. Microsomal triglyceride transfer protein (MTP) regulation in HepG2 cells: insulin negatively regulates MTP gene expression. J Lipid Res. 1995;36:1073-81.
43. Wetterau JR, Gregg RE, Harrity TW, Arbeeny C, Cap M, Connolly F, et al. An MTP inhibitor that normalizes atherogenic lipoprotein levels in WHHL rabbits. Science. 1998;282:751-4.
44. Shiomi M, Ito T. MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion. Eur J Pharmacol. 2001;431:127-31.
45. Chandler CE, Wilder DE, Pettini JL, Savoy YE, Petras SF, Chang G, et al. CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans. J Lipid Res. 2003;44:1887-901.
46. Aggarwal D, West KL, Zern TL, Shrestha S, Vergara-Jimenez M, Fernandez ML. JTT-130, a microsomal triglyceride transfer protein (MTP) inhibitor lowers plasma triglycerides and LDL cholesterol concentrations without increasing hepatic triglycerides in guinea pigs. BMC Cardiovasc Disord. 2005;5:30.
47. Sacks FM, Stanesa M, Hegele RA. Severe hypertriglyceridemia with pancreatitis: thirteen years' treatment with lomitapide. JAMA internal medicine. 2014;174:443-7.
48. Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med. 2007;356:148-56.
49. Lomitapide. Am J Cardiovasc Drugs. 2011;11:347-52.
50. Perry CM. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia. Am J Cardiovasc Drugs. 2013;13:285-96.
51. Tuteja S DD, Dunbar RL, Movva R, Gadi R, Bloedon LT, et al. Pharmacokinetic interactions of the microsomal triglyceride transfer protein inhibitor, lomitapide, with drugs commonly used in the management of hypercholesterolemia. Pharmacotherapy. 2014;34:227-39.
52. Samaha FF, McKenney J, Bloedon LT, Sasiela WJ, Rader DJ. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2008;5:497-505.
53. Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381:40-6.
54. Goldstein JL, Dana SE, Brunschede GY, Brown MS. Genetic heterogeneity in familial hypercholesterolemia: evidence for two different mutations affecting functions of low-density lipoprotein receptor. Proc Natl Acad Sci U S A. 1975;72:1092-6.
55. Leitersdorf E, Tobin EJ, Davignon J, Hobbs HH. Common low-density lipoprotein receptor mutations in the French Canadian population. J Clin Invest. 1990;85:1014-23.
56. Visser ME, Akdim F, Tribble DL, Nederveen AJ, Kwoh TJ, Kastelein JJ, et al. Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia. J Lipid Res. 2010;51:1057-62.
57. Lieu HD, Withycombe SK, Walker Q, Rong JX, Walzem RL, Wong JS, et al. Eliminating atherogenesis in mice by switching off hepatic lipoprotein secretion. Circulation. 2003;107:1315-21.
58. Verges B. Abnormal hepatic apolipoprotein B metabolism in type 2 diabetes. Atherosclerosis. 2010;211:353-60.
59. Costandi J, Melone M, Zhao A, Rashid S. Human resistin stimulates hepatic overproduction of atherogenic ApoB-containing lipoprotein particles by enhancing ApoB stability and impairing intracellular insulin signaling. Circ Res. 2011;108:727-42.
60. Hewing B, Parathath S, Mai CK, Fiel MI, Guo L, Fisher EA. Rapid regression of atherosclerosis with MTP inhibitor treatment. Atherosclerosis. 2013; 227:125-9.
61. Rodenburg J, Vissers MN, Wiegman A, van Trotsenburg AS, van der Graaf A, de Groot E, et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation. 2007;116:664-8.
62. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study. Cardiovasc Drugs Therapy. 2005;19:403-14.